Global disease experts say little is known about China's experience with long-term COVID effects thought to have afflicted millions with debilitating fatigue, brain fog and other symptoms
India in March put a temporary hold on all major exports of the AstraZeneca coronavirus shot made by the family-run firm in order to inoculate its own citizens as the country struggled to manage a devastating surge of COVID-19 cases.
The resumption of exports was linked to SII surpassing its original target to produce 1 billion doses of Covishield by the end of the year, the company said, adding that the total number of vaccine doses produced have crossed 1.25 billion.
SII said its supply of doses via COVAX was expected to increase substantially into the first quarter of 2022.
To boost its COVID-19 vaccine output further, SII will bring into production other vaccines under licence, including COVOVAX, from US-based Novavax.